Zurbrügg H R, Knollmann F, Musci M, Wied M, Bauer M, Chavez T, Krukenberg A, Hetzer R
Deutsches Herzzentrum Berlin, Germany.
Ann Thorac Surg. 2000 Nov;70(5):1536-40. doi: 10.1016/s0003-4975(00)01997-4.
Complete arterial revascularization may be unsafe in patients with a high operative risk. In patients with varicose ectatic veins, the biocompound technique, which uses unsuitable autologous veins, enables the surgeon to influence the bypass graft wall stress levels and diameter. This report summarizes the 3-year patency of 53 patients, the survival rate of 200 patients, and operative technical considerations.
Biocompound grafts were used for aortocoronary bypass in 200 patients who were considered inappropriate subjects for complete arterial revascularization and who had unsuitable saphenous veins.
The mortality rate (30 days) of 200 patients was 3.5%. The 3-year survival rate was 88.5%. The patency rate of the left internal thoracic artery (LITA) after 3 years was 97.3%, of the native vein was 68.7%, and of the biocompound graft was 68.3%. The LITA showed a superior patency rate (p = < 0.05).
The LITA is the first choice in coronary bypass operation. The biocompound technique is a reliable method to achieve complete revascularization in patients with a lack of suitable saphenous veins.
对于手术风险高的患者，完全动脉血运重建可能不安全。在患有静脉曲张扩张的患者中，使用不合适的自体静脉的生物复合技术能使外科医生影响旁路移植血管壁的应力水平和直径。本报告总结了53例患者的3年通畅率、200例患者的生存率以及手术技术要点。
对200例被认为不适合进行完全动脉血运重建且大隐静脉不合适的患者，采用生物复合移植物进行主动脉冠状动脉旁路移植术。
200例患者的30天死亡率为3.5%。3年生存率为88.5%。3年后左内乳动脉（LITA）的通畅率为97.3%，自体静脉为68.7%，生物复合移植物为68.3%。LITA显示出更高的通畅率（p = < 0.05）。
LITA是冠状动脉旁路手术的首选。生物复合技术是在缺乏合适大隐静脉的患者中实现完全血运重建的可靠方法。
